IBDEI2HD ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,39611,1,4,0)
 ;;=4^C82.99
 ;;^UTILITY(U,$J,358.3,39611,2)
 ;;=^5001550
 ;;^UTILITY(U,$J,358.3,39612,0)
 ;;=C82.90^^152^2000^76
 ;;^UTILITY(U,$J,358.3,39612,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39612,1,3,0)
 ;;=3^Follicular Lymphoma Unspec,Unspec Site
 ;;^UTILITY(U,$J,358.3,39612,1,4,0)
 ;;=4^C82.90
 ;;^UTILITY(U,$J,358.3,39612,2)
 ;;=^5001541
 ;;^UTILITY(U,$J,358.3,39613,0)
 ;;=R59.1^^152^2000^61
 ;;^UTILITY(U,$J,358.3,39613,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39613,1,3,0)
 ;;=3^Enlarged Lymph Nodes,Generalized
 ;;^UTILITY(U,$J,358.3,39613,1,4,0)
 ;;=4^R59.1
 ;;^UTILITY(U,$J,358.3,39613,2)
 ;;=^5019530
 ;;^UTILITY(U,$J,358.3,39614,0)
 ;;=C91.40^^152^2000^80
 ;;^UTILITY(U,$J,358.3,39614,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39614,1,3,0)
 ;;=3^Hairy Cell Leukemia,Not in Remission
 ;;^UTILITY(U,$J,358.3,39614,1,4,0)
 ;;=4^C91.40
 ;;^UTILITY(U,$J,358.3,39614,2)
 ;;=^5001771
 ;;^UTILITY(U,$J,358.3,39615,0)
 ;;=C91.42^^152^2000^78
 ;;^UTILITY(U,$J,358.3,39615,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39615,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Relapse
 ;;^UTILITY(U,$J,358.3,39615,1,4,0)
 ;;=4^C91.42
 ;;^UTILITY(U,$J,358.3,39615,2)
 ;;=^5001773
 ;;^UTILITY(U,$J,358.3,39616,0)
 ;;=C91.41^^152^2000^79
 ;;^UTILITY(U,$J,358.3,39616,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39616,1,3,0)
 ;;=3^Hairy Cell Leukemia,In Remission
 ;;^UTILITY(U,$J,358.3,39616,1,4,0)
 ;;=4^C91.41
 ;;^UTILITY(U,$J,358.3,39616,2)
 ;;=^5001772
 ;;^UTILITY(U,$J,358.3,39617,0)
 ;;=D57.01^^152^2000^81
 ;;^UTILITY(U,$J,358.3,39617,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39617,1,3,0)
 ;;=3^Hb-SS Disease w/ Acute Chest Syndrome
 ;;^UTILITY(U,$J,358.3,39617,1,4,0)
 ;;=4^D57.01
 ;;^UTILITY(U,$J,358.3,39617,2)
 ;;=^5002307
 ;;^UTILITY(U,$J,358.3,39618,0)
 ;;=D57.00^^152^2000^82
 ;;^UTILITY(U,$J,358.3,39618,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39618,1,3,0)
 ;;=3^Hb-SS Disease w/ Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,39618,1,4,0)
 ;;=4^D57.00
 ;;^UTILITY(U,$J,358.3,39618,2)
 ;;=^5002306
 ;;^UTILITY(U,$J,358.3,39619,0)
 ;;=D57.02^^152^2000^83
 ;;^UTILITY(U,$J,358.3,39619,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39619,1,3,0)
 ;;=3^Hb-SS Disease w/ Splenic Sequestration
 ;;^UTILITY(U,$J,358.3,39619,1,4,0)
 ;;=4^D57.02
 ;;^UTILITY(U,$J,358.3,39619,2)
 ;;=^5002308
 ;;^UTILITY(U,$J,358.3,39620,0)
 ;;=D68.32^^152^2000^85
 ;;^UTILITY(U,$J,358.3,39620,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39620,1,3,0)
 ;;=3^Hemorrhagic Disorder d/t Extrinsic Circulating Anticoagulants
 ;;^UTILITY(U,$J,358.3,39620,1,4,0)
 ;;=4^D68.32
 ;;^UTILITY(U,$J,358.3,39620,2)
 ;;=^5002357
 ;;^UTILITY(U,$J,358.3,39621,0)
 ;;=C22.2^^152^2000^86
 ;;^UTILITY(U,$J,358.3,39621,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39621,1,3,0)
 ;;=3^Hepatoblastoma
 ;;^UTILITY(U,$J,358.3,39621,1,4,0)
 ;;=4^C22.2
 ;;^UTILITY(U,$J,358.3,39621,2)
 ;;=^5000935
 ;;^UTILITY(U,$J,358.3,39622,0)
 ;;=D58.9^^152^2000^88
 ;;^UTILITY(U,$J,358.3,39622,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39622,1,3,0)
 ;;=3^Hereditary Hemolytic Anemia,Unspec
 ;;^UTILITY(U,$J,358.3,39622,1,4,0)
 ;;=4^D58.9
 ;;^UTILITY(U,$J,358.3,39622,2)
 ;;=^5002322
 ;;^UTILITY(U,$J,358.3,39623,0)
 ;;=C81.99^^152^2000^89
 ;;^UTILITY(U,$J,358.3,39623,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,39623,1,3,0)
 ;;=3^Hodgkin Lymphoma,Extranodal/Solid Organ Sites
 ;;^UTILITY(U,$J,358.3,39623,1,4,0)
 ;;=4^C81.99
